BioVector? BCWM.1 人類華氏巨球蛋白血癥細(xì)胞系 / BCWM.1 Human Waldenstr?m’s Macroglobulinemia Cell Line

通用定義 / General Definition:

BioVector? BCWM.1 是一種源自華氏巨球蛋白血癥（Waldenstr?m’s Macroglobulinemia, WM）患者骨髓的淋巴漿細(xì)胞樣淋巴瘤細(xì)胞系。該細(xì)胞系具有典型的 $MYD88^{L265P}$ 突變，這是 WM 患者中最常見的遺傳改變。作為研究 WM 病理生理學(xué)、IgM 分泌機(jī)制以及評(píng)估布魯頓酪氨酸激酶（BTK）抑制劑等新型靶向藥物的支柱模型，BioVector? BCWM.1 在血液腫瘤學(xué)研究中具有極高的應(yīng)用價(jià)值。

BioVector? BCWM.1 is a lymphoplasmacytic lymphoma cell line derived from the bone marrow of a patient with Waldenstr?m’s Macroglobulinemia (WM). The cell line features the signature $MYD88^{L265P}$ mutation, which is present in the vast majority of WM patients. As a cornerstone model for studying WM pathophysiology, IgM secretion mechanisms, and evaluating novel targeted therapies such as Bruton’s Tyrosine Kinase (BTK) inhibitors, BioVector? BCWM.1 is highly instrumental in hemato-oncology research.

BioVector? BCWM.1 細(xì)胞系技術(shù)說明書 (Cell Line Datasheet)

中文版說明書

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? BCWM.1 人華氏巨球蛋白血癥細(xì)胞

• 細(xì)胞來源： 人類 (Human)

• 組織來源： 骨髓 (Bone Marrow)

• 生長特性： 懸浮生長 (Suspension)

• 細(xì)胞形態(tài)： 淋巴母細(xì)胞樣/漿細(xì)胞樣

2. 培養(yǎng)條件

• 基礎(chǔ)培養(yǎng)基： BioVector? RPMI 1640 培養(yǎng)基

• 血清添加： 10% - 20% BioVector? 胎牛血清 (FBS)（建議初始傳代使用 20% 以增強(qiáng)活力）

• 培養(yǎng)環(huán)境： 37°C，5% $CO_2$，飽和濕度

3. 細(xì)胞應(yīng)用

• 突變研究：$MYD88^{L265P}$ 介導(dǎo)的信號(hào)轉(zhuǎn)導(dǎo)研究。

• 藥物篩選： 評(píng)估 BTK 抑制劑（如伊布替尼）及其他小分子藥物的療效。

• 免疫球蛋白研究： 單克隆 IgM 分泌及 B 細(xì)胞分化機(jī)制探索。

4. 注意事項(xiàng)

• 生長密度： 懸浮細(xì)胞需保持在適當(dāng)密度，建議維持在 $5 \times 10^5$ 至 $2 \times 10^6$ cells/mL 之間。

• 結(jié)團(tuán)現(xiàn)象： 細(xì)胞在生長旺盛時(shí)可能出現(xiàn)輕微結(jié)團(tuán)，屬于正常生理狀態(tài)，輕柔吹打即可散開。

English Datasheet

1. General Product Information

• Product Name: BioVector? BCWM.1 Human Waldenstr?m’s Macroglobulinemia Cell Line

• Organism: Human

• Tissue Source: Bone Marrow

• Growth Properties: Suspension

• Morphology: Lymphoblast-like / Plasmacytoid

2. Culture Conditions

• Basal Medium: BioVector? RPMI 1640 Medium

• Serum Supplement: 10% - 20% BioVector? Fetal Bovine Serum (FBS) (20% is recommended for recovery and early passages)

• Incubation: 37°C, 5% $CO_2$, Saturated Humidity

3. Applications

• Mutation Studies: Research on $MYD88^{L265P}$ mediated signaling pathways.

• Drug Screening: Evaluation of BTK inhibitors (e.g., Ibrutinib) and other small molecule therapeutics.

• Immunoglobulin Research: Exploration of monoclonal IgM secretion and B-cell differentiation mechanisms.

4. Key Usage Notes

• Cell Density: Maintain suspension cultures between $5 \times 10^5$ and $2 \times 10^6$ cells/mL for optimal growth.

• Clumping: Slight cell clumping may occur during active proliferation; this is normal and can be dispersed by gentle pipetting.

Note: Handle BioVector? BCWM.1 cells under Biosafety Level 2 (BSL-2) conditions. To ensure the stability of the $MYD88$ mutation profile and high IgM secretion, the consistent use of BioVector? RPMI 1640 Medium and BioVector? Fetal Bovine Serum is highly recommended.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

E-mail: [email protected]

http://www.nedfriskphoto.com